Cargando…

Association of Plasma Epstein-Barr Virus DNA With Outcomes for Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma Receiving Anti–Programmed Cell Death 1 Immunotherapy

IMPORTANCE: Anti–programmed cell death 1 (anti–PD-1) immunotherapy features a durable response and improved survival in a small subset of patients with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC). The association between plasma Epstein-Barr virus (EBV) DNA titer dynamics and efficacy o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Jian-Ying, Wei, Xiao-Li, Ren, Chao, Zhang, Yang, Hu, Yao-Fang, Li, Jia-Yu, Chen, Jun-Liang, Wang, Yi-Qin, Han, Fei, Wang, Feng-Hua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2022
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8889459/ https://www.ncbi.nlm.nih.gov/pubmed/35230439 http://dx.doi.org/10.1001/jamanetworkopen.2022.0587

Ejemplares similares

Assessment of Survival Model Performance Following Inclusion of Epstein-Barr Virus DNA Status in Conventional TNM Staging Groups in Epstein-Barr Virus–Related Nasopharyngeal Carcinoma
por: Li, Wang-Zhong, et al.
Publicado: (2021)

Synergistic Association of Hepatitis B Surface Antigen and Plasma Epstein-Barr Virus DNA Load on Distant Metastasis in Patients With Nasopharyngeal Carcinoma
por: Li, Haojiang, et al.
Publicado: (2023)

Plasma Circulating Tumor Epstein–Barr Virus for the Surveillance of Cancer Progression in Bone-Only Metastatic Nasopharyngeal Carcinoma
por: Liu, Guo-Ying, et al.
Publicado: (2022)

Clinical value of a plasma Epstein–Barr virus DNA assay in the diagnosis of recurrent or metastatic nasopharyngeal carcinoma: a meta-analysis
por: Peng, Haiqin, et al.
Publicado: (2019)

Clinical characteristics and prognostic value of pre‐retreatment plasma epstein‐barr virus DNA in locoregional recurrent nasopharyngeal carcinoma
por: Liu, Ming‐Zhu, et al.
Publicado: (2019)

Epstein-Barr virus and nasopharyngeal carcinoma
por: Young, Lawrence S., et al.
Publicado: (2014)

Plasma Epstein-Barr virus DNA as a biomarker for nasopharyngeal carcinoma
por: Chan, K.C. Allen
Publicado: (2014)

Positivity of both plasma Epstein–Barr virus DNA and serum Epstein–Barr virus capsid specific immunoglobulin A is a better prognostic biomarker for nasopharyngeal carcinoma
por: Zhao, Fei-Peng, et al.
Publicado: (2014)

Individualized induction chemotherapy by pre-treatment plasma Epstein-Barr viral DNA in advanced nasopharyngeal carcinoma
por: Zhang, Jian, et al.
Publicado: (2018)

Progesterone analogues reduce plasma Epstein–Barr virus DNA load and improve pain control in recurrent/metastatic nasopharyngeal carcinoma patients under supportive care
por: Hung, Chia-Yen, et al.
Publicado: (2017)

Prevalence and significance of plasma Epstein-Barr Virus DNA level in nasopharyngeal carcinoma
por: Prayongrat, Anussara, et al.
Publicado: (2017)

Targeting Epstein-Barr Virus in Nasopharyngeal Carcinoma
por: Hau, Pok Man, et al.
Publicado: (2020)

The role of Epstein–Barr virus in nasopharyngeal carcinoma
por: Su, Zhi Yi, et al.
Publicado: (2023)

The evolution of Epstein-Barr virus detection in nasopharyngeal carcinoma
por: Li, You Quan, et al.
Publicado: (2018)

Role of Epstein-Barr Virus in the Development of Nasopharyngeal Carcinoma
por: Zhang, Hui, et al.
Publicado: (2017)

Plasma Epstein-Barr virus DNA and risk of nasopharyngeal carcinoma in a prospective seropositive population
por: Chen, Wen-Jie, et al.
Publicado: (2021)

Clinical Implications of Plasma Epstein–Barr Virus DNA in Children and Adolescent Nasopharyngeal Carcinoma Patients Receiving Intensity-Modulated Radiotherapy
por: Qiu, Wenze, et al.
Publicado: (2020)

Prognostic Correlations between ABO Blood Group and Pre-Treatment Plasma Epstein-Barr Virus DNA in Patients with Nasopharyngeal Carcinoma Receiving Intensity-Modulated Radiotherapy
por: Peng, Hao, et al.
Publicado: (2016)

Microsatellite Instability, Epstein–Barr Virus, and Programmed Cell Death Ligand 1 as Predictive Markers for Immunotherapy in Gastric Cancer
por: Yu, Hung-Yuan, et al.
Publicado: (2022)

Roles of Inflammasomes in Epstein–Barr Virus-Associated Nasopharyngeal Cancer
por: Looi, Chin King, et al.
Publicado: (2021)

Prognostic value of serum Epstein–Barr virus antibodies in patients with nasopharyngeal carcinoma and undetectable pretreatment Epstein–Barr virus DNA
por: Yao, Ji‐Jin, et al.
Publicado: (2017)

Risk stratification based on change in plasma Epstein-Barr virus DNA load after treatment in nasopharyngeal carcinoma
por: Zhang, Yuan, et al.
Publicado: (2016)

Impact of Plasma Epstein-Barr Virus-DNA and Tumor Volume on Prognosis of Locally Advanced Nasopharyngeal Carcinoma
por: Chen, Meng, et al.
Publicado: (2015)

The impact of plasma epstein–barr virus DNA and fibrinogen on nasopharyngeal carcinoma prognosis: an observational study
por: Tang, L-Q, et al.
Publicado: (2014)

The clinicopathological significance and predictive value for immunotherapy of programmed death ligand-1 expression in Epstein-Barr virus-associated gastric cancer
por: Wei, Xiao-Li, et al.
Publicado: (2021)

The emerging role of Epstein-Barr virus encoded microRNAs in nasopharyngeal carcinoma
por: Fan, Chunmei, et al.
Publicado: (2018)

Identification of genes involved in Epstein-Barr virus-associated nasopharyngeal carcinoma
por: Wang, Junguo, et al.
Publicado: (2016)

Immunotherapy for Epstein-Barr Virus-Related Lymphomas
por: Kennedy-Nasser, Alana A., et al.
Publicado: (2009)

Correlation of nasopharyngeal carcinoma with rare earth elements and the Epstein-Barr virus
por: Zhang, Xiangmin, et al.
Publicado: (2018)

Epstein-Barr virus infection and persistence in nasopharyngeal epithelial cells
por: Tsang, Chi Man, et al.
Publicado: (2014)

Epstein-Barr Virus Mediated Signaling in Nasopharyngeal Carcinoma Carcinogenesis
por: Richardo, Timmy, et al.
Publicado: (2020)

Nasopharyngeal Carcinoma: The Role of the EGFR in Epstein–Barr Virus Infection
por: Peng, Xintong, et al.
Publicado: (2021)

Prognostic Impact of Plasma Epstein-Barr Virus DNA in Patients with Nasopharyngeal Carcinoma Treated using Intensity-Modulated Radiation Therapy
por: Peng, Hao, et al.
Publicado: (2016)

Integration Profiling Between Plasma Lipidomics, Epstein–Barr Virus and Clinical Phenomes in Nasopharyngeal Carcinoma Patients
por: Huang, Yi, et al.
Publicado: (2022)

Ubiquitous Distribution of Epstein–Barr Virus and the Highly Uneven Distribution of Nasopharyngeal Carcinoma
por: Wang, Chu-Qiong, et al.
Publicado: (2016)

Oral Microbiota Alteration and Roles in Epstein-Barr Virus Reactivation in Nasopharyngeal Carcinoma
por: Liao, Ying, et al.
Publicado: (2023)

Integrating pre- and post-treatment Plasma Epstein-Barr Virus DNA levels for better prognostic prediction of Nasopharyngeal Carcinoma
por: Li, Wanxia, et al.
Publicado: (2021)

Prognostic Value of Plasma Epstein-Barr Virus DNA Levels Pre- and Post-Neoadjuvant Chemotherapy in Patients With Nasopharyngeal Carcinoma
por: Zhu, Lisheng, et al.
Publicado: (2021)

Plasma Epstein-Barr viral DNA complements TNM classification of nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy
por: Zhang, Lu, et al.
Publicado: (2015)

Nasopharyngeal Epstein‐Barr virus DNA loads in high‐risk nasopharyngeal carcinoma families: Familial aggregation and host heritability
por: Zheng, Mei‐Qi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_p6lav4ej45002l13s06vfv5a8r